Delivery Order SPE2DB20D3303-SPE2DB25FA4BK
- Not listed
- The Defense Logistics Agency awarded a $1,687.48 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for ProQuad vials with a completion date of August 29, 2025. This firm fixed-price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationships with DLA for pharmaceutical supply to...
- The Defense Logistics Agency awarded a $1,654.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 20, 2025, with a completion date of September 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The order will be performed at AmerisourceBergen's corporate headquarters in...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $8,437.20 by the Defense Logistics Agency on September 2, 2025, for the supply of ProQuad vials with a completion date of September 23, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the pharmaceutical distributor's Corporate Office division. The place of performance is AmerisourceBergen's headquarters in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a $13,367.20 delivery order to AmerisourceBergen Drug Corp for ProQuad vials on September 16, 2025, with an ultimate completion date of October 7, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. ProQuad is a combination vaccine used for immunization against measles, mumps, rubella, and varicella, representing a...
- The Defense Logistics Agency awarded a $16,543.30 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product, with a completion date of August 21, 2025. This competitive award (no set-aside used) was issued under a firm fixed-price structure and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,055.26 to AmerisourceBergen Drug Corp for ProQuad vials on August 5, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a $3,308.68 delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 6, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price, non-set-aside contract is performed at the awardee's Conshohocken, Pennsylvania location. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of ProQuad vials, valued at $8,354.50 with a completion date of September 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procedures. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $16.87K delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with performance in Conshohocken, Pennsylvania and an ultimate completion date of August 15, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation. ProQuad is a combination vaccine for measles, mumps, rubella, and varicella, which aligns with AmerisourceBergen's established role as a critical federal pharmaceutical and medical supply...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA4BKDelivery Order
The Defense Logistics Agency awarded a $16,709 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for ProQuad vials with an ultimate completion date of October 15, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. ProQuad is a combination vaccine protecting against measles, mumps, rubella, and varicella, essential for maintaining immunization readiness across the Department of Defense healthcare system. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen leverages its extensive supply chain infrastructure to fulfill federal procurement requirements for vaccines, medications, and medical supplies supporting military and veteran healthcare systems. This transaction exemplifies the company's ongoing role as a preferred pharmaceutical provider for DLA, demonstrating its capability to deliver specialized medical commodities on an accelerated timeline to support federal health security needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.7k | 9/23/25 |